Cargando…
PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429529/ http://dx.doi.org/10.1097/01.HS9.0000850248.63603.48 |
_version_ | 1784779472296214528 |
---|---|
author | Daver, N. G. Wei, A. H. Stein, E. M. DeAngelo, D. J. Pathak, D. Xu, Y. Grzesiak, S. Venditti, A. |
author_facet | Daver, N. G. Wei, A. H. Stein, E. M. DeAngelo, D. J. Pathak, D. Xu, Y. Grzesiak, S. Venditti, A. |
author_sort | Daver, N. G. |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9429529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-94295292022-08-31 PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY Daver, N. G. Wei, A. H. Stein, E. M. DeAngelo, D. J. Pathak, D. Xu, Y. Grzesiak, S. Venditti, A. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429529/ http://dx.doi.org/10.1097/01.HS9.0000850248.63603.48 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
spellingShingle | Publication Only Daver, N. G. Wei, A. H. Stein, E. M. DeAngelo, D. J. Pathak, D. Xu, Y. Grzesiak, S. Venditti, A. PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY |
title | PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY |
title_full | PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY |
title_fullStr | PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY |
title_full_unstemmed | PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY |
title_short | PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY |
title_sort | pb1849: trial in progress: phase ib/ii study of siremadlin in combination with venetoclax + azacitidine in patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy |
topic | Publication Only |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429529/ http://dx.doi.org/10.1097/01.HS9.0000850248.63603.48 |
work_keys_str_mv | AT daverng pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy AT weiah pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy AT steinem pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy AT deangelodj pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy AT pathakd pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy AT xuy pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy AT grzesiaks pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy AT vendittia pb1849trialinprogressphaseibiistudyofsiremadlinincombinationwithvenetoclaxazacitidineinpatientswithacutemyeloidleukemiaamlwhoareineligibleforintensivechemotherapy |